Why Moderna Stock Plummeted by Almost 7% Today
A quarterly bottom line that was deep in the red sent (NASDAQ: MRNA) shareholders booking for the exits on Thursday. Following the release of its third-quarter figures, the high-profile biotech's stock lost nearly 7% of its value on the day. By contrast, the S 500 index was in positive territory, closing the day 1.9% higher.
That morning, Moderna published its latest earnings release. This showed that the company's revenue was slightly over $1.8 billion, which compares unfavorably to the third-quarter 2022 tally of almost $3.4 billion. On the bright side, that take was well higher than the $1.4 billion average analyst estimate.
The situation was far more dramatic on the bottom line. The biotech flipped violently to a generally accepted accounting principles (GAAP) loss of more than $3.6 billion ($9.53 per share) from the year-ago profit of more than $1.0 billion. This almost certainly caught those analysts by surprise, as collectively, they were expecting a shortfall of only $1.90 per share.
Source Fool.com
Moderna Inc. Aktie
Die Community bevorzugt klar Moderna Inc. mit vielen Buy- und nur wenigen Sell-Einschätzungen.
Eine erhebliche Steigerung um mehr als 50% ist für Moderna Inc. mit einem Kursziel von 129 € im Vergleich zum aktuellen Kurs von 65.76 € zu erwarten.
